Author

C. Qing

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Research Focus:benchmarking· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Approach:mechanistic / dynamical model· 1

Frequent Co-Authors

F. Jiang· 2 shared J. Shen· 2 shared J.-Y. Lang· 2 shared X. Kong· 2 shared D. Liu· 1 shared F. Peng· 1 shared H. Xiang· 1 shared H. Zhu· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Jiang

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cohesin mutation sensitizes cancer cells to anti-PD-1 therapy through endogenous retrovirus-mediated PD-L1 upregulation

Y. Han, F. Peng, Y. Chang, T. Liu, J. Shen, Z. Chen, P. Zhou, F. Jiang, H. Xiang, H. Zhu, C. Qing, X. Kong, J. Ding, J.-Y. Lang

This study shows cohesin mutations enhance cancer cell sensitivity to anti-PD-1 therapy by increasing PD-L1 through endogenous retrovirus activation.

bioRxiv · Feb 19, 2022 · PreprintCancer Biology

Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complex

J.-Y. Lang, X. Wang, Q. Xie, Y. Ji, J. Shen, Y. Zhang, F. Jiang, X. Kong, D. Liu, L. Zheng, C. Qing

This study identifies the ERK2-p53 complex as a therapeutic target in KRAS-mutant stomach/colorectal cancers, showing that disrupting it with MEK1/2 and ERK2 inhibitors induces apoptosis.

bioRxiv · Aug 12, 2020Cancer Biology